Gilead Sciences
GILD
₹9,947
Share price
1.06%
Change (1 day)
52.82%
Change (1 year)
Categories
Earnings for Gilead Sciences (GILD)
Earnings in 2025 (TTM): ₹578.12 Billion
According to Gilead Sciences's latest financial reports the company's current earnings are ₹28.73 Billion. In 2024 the company made an earning of ₹60.08 Billion a decrease over its 2023 earnings that were of ₹597.28 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Gilead Sciences from 1991 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | ₹578.12 B | 862.18% |
| 2024 | ₹60.08 B | -89.94% |
| 2023 | ₹597.28 B | 17.97% |
| 2022 | ₹506.28 B | -29.77% |
| 2021 | ₹720.84 B | 395.99% |
| 2020 | ₹145.33 B | -67.66% |
| 2019 | ₹449.33 B | -33.84% |
| 2018 | ₹679.13 B | -42.35% |
| 2017 | ₹1.178 T | -20.87% |
| 2016 | ₹1.488 T | -21.06% |
| 2015 | ₹1.886 T | 45.8% |
| 2014 | ₹1.293 T | 253.01% |
| 2013 | ₹366.45 B | 16.51% |
| 2012 | ₹314.53 B | -1.07% |
| 2011 | ₹317.92 B | -6.71% |
| 2010 | ₹340.79 B | 11.75% |
| 2009 | ₹304.95 B | 29.5% |
| 2008 | ₹235.48 B | 19.11% |
| 2007 | ₹197.70 B | -455.74% |
| 2006 | -₹55.58 Billion | -154.93% |
| 2005 | ₹101.16 B | 76.99% |
| 2004 | ₹57.16 B | -266.16% |
| 2003 | -₹34.41 Billion | -638.24% |
| 2002 | ₹6.39 B | 31.5% |
| 2001 | ₹4.86 B | -242.15% |
| 2000 | -₹3.42 Billion | -40.2% |
| 1999 | -₹5.72 Billion | 31.85% |
| 1998 | -₹4.34 Billion | 8.73% |
| 1997 | -₹3.99 Billion | 27.22% |
| 1996 | -₹3.14 Billion | |
| 1994 | -₹2.99 Billion | 26.57% |
| 1993 | -₹2.36 Billion | 46.49% |
| 1992 | -₹1.62 Billion | 362.5% |
| 1991 | -₹0.35 Billion |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | ₹579.08 B | -2.56% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | -₹24.13 Billion | -104.06% | 🇺🇸 USA |
 AbbVie ABBV | ₹315.40 B | -46.93% | 🇺🇸 USA |
 Illumina ILMN | -₹68.01 Billion | -111.44% | 🇺🇸 USA |
 Biogen BIIB | ₹152.59 B | -74.32% | 🇺🇸 USA |
 Pfizer PFE | ₹900.49 B | 51.52% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹2.386 T | 301.58% | 🇺🇸 USA |
 Eli Lilly LLY | ₹1.184 T | 99.27% | 🇺🇸 USA |
 Merck MRK | ₹1.867 T | 214.29% | 🇺🇸 USA |